Form 4: Acrivon Therapeutics CFO Rasmus Holm-Jorgensen Reports Stock Transaction
SEC Form 4 Filing
Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 14, 2025, Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, Inc., had shares of common stock withheld by the issuer to satisfy mandatory tax withholding requirements.
- A total of 434 shares were withheld at a price of $5.42 per share.
- Following the transaction, Holm-Jorgensen directly owns 26,088 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions, and it doesn't inherently convey positive or negative sentiment. It's a neutral disclosure.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and is a standard practice for company executives. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine tax-related withholding of shares.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock transaction (shares withheld for tax obligations). |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Acrivon Therapeutics, Form 4, Insider Trading, Rasmus Holm-Jorgensen, CFO, Stock Transaction, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.